Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 5/20 | 0.47 |
| ▸ | CTSK | P43235 | 5/20 | 0.47 |
| ▸ | CTSS | P25774 | 4/20 | 0.47 |
| ▸ | CTSB | P07858 | 4/20 | 0.47 |
| ▸ | CASP1 | P29466 | 4/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31376796 | 0.89 | GAA (0.50) | GAACTSLCTSKCTSSCTSB | |
| SCHEMBL29062806 | 0.89 | GAA (0.50) | GAACTSLCTSKCTSSCTSB | |
| SCHEMBL8312973 | 0.83 | CTSK (0.56) | CTSLCTSKCTSSCTSB | |
| SCHEMBL6506646 | 0.82 | CASP1 (0.59) | KYNUALDH1A1ALOX15CTSLCTSK | |
| SCHEMBL8142600 | 0.81 | CASP1 (0.56) | KYNUALDH1A1ALOX15CTSLCTSK | |
| SCHEMBL13914058 | 0.81 | CTSK (0.53) | CTSLCTSKCTSSCTSB | |
| SCHEMBL29062923 | 0.81 | ALDH1A1 (0.50) | KYNUALDH1A1ALOX15CTSLCTSK | |
| SCHEMBL29062922 | 0.81 | ALDH1A1 (0.50) | KYNUALDH1A1ALOX15CTSLCTSK | |
| SCHEMBL8296213 | 0.78 | CASP1 (0.61) | KYNUALDH1A1ALOX15CTSLCTSK | |
| SCHEMBL6497607 | 0.78 | CASP1 (0.61) | KYNUALDH1A1ALOX15CTSLCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025011610-A1 | AMIDE DERIVATIVE, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-16 | — | — | WO | disclosed |
| US-20230340018-A1 | MPRO CYSTEINE PROTEASE INHIBITORS | ANIXA BIOSCIENCES, INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2022040186-A1 | MPRO CYSTEINE PROTEASE INHIBITORS | ANIXA BIOSCIENCES, INC. (US) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340018-A1 | MPRO CYSTEINE PROTEASE INHIBITORS | SERPINB1, PREP, PRCP | KYNU 2096/4885GAA 299/4885ALDH1A1 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.